The results were significant: Average weight loss of 20.7% of starting body weight over a span of 72 weeks among participants who stayed on treatment, compared to 17.5% with the standard 2.4 mg dose
Early data suggests Retatrutide may preserve lean mass slightly better than Tirzepatide, though direct head-to-head comparisons specifically examining body composition in training populations are not available
& Yellon, D
Key advancements in peptide technology for triple receptor agonism: Application of computational modeling to peptide-receptor binding Fatty acid substitution for extended stability and duration -helical design for superior receptor fit Structure-based design to hone drug action and safety Engineering peptides that simultaneously bind and stimulate multiple receptors Clinical Implications With retatrutide, a triple receptor agonist that has been studied in clinical trials for obesity and metabolic diseases, including type 2 diabetes and MASLD
PCOS Sisters Metabolic Weight Loss Program Symptoms PCOS Treatment Details For many women, losing weight is already a challengebut with PCOS, it can feel nearly impossible
Reaching week twelve with a stable dose represents a meaningful hurdle cleared, after which continuation rates increase substantially